Beigene Ltd (NASDAQ:BGNE) CMO Jane Huang sold 3,000 shares of Beigene stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $209.93, for a total value of $629,790.00. Following the completion of the transaction, the chief marketing officer now owns 326,247 shares in the company, valued at $68,489,032.71. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Jane Huang also recently made the following trade(s):

  • On Tuesday, July 7th, Jane Huang sold 3,921 shares of Beigene stock. The shares were sold at an average price of $200.00, for a total value of $784,200.00.
  • On Friday, June 26th, Jane Huang sold 2,079 shares of Beigene stock. The shares were sold at an average price of $200.29, for a total value of $416,402.91.
  • On Monday, June 29th, Jane Huang sold 1,935 shares of Beigene stock. The shares were sold at an average price of $190.83, for a total value of $369,256.05.
  • On Monday, June 8th, Jane Huang sold 631 shares of Beigene stock. The shares were sold at an average price of $170.84, for a total value of $107,800.04.
  • On Friday, May 29th, Jane Huang sold 1,500 shares of Beigene stock. The shares were sold at an average price of $163.86, for a total value of $245,790.00.

NASDAQ BGNE opened at $209.00 on Friday. The company has a quick ratio of 7.89, a current ratio of 7.96 and a debt-to-equity ratio of 0.08. The stock’s 50 day moving average is $202.74 and its two-hundred day moving average is $168.21. Beigene Ltd has a 1-year low of $114.41 and a 1-year high of $256.01.

Beigene (NASDAQ:BGNE) last announced its earnings results on Monday, May 11th. The company reported ($4.70) EPS for the quarter, topping the consensus estimate of ($4.85) by $0.15. The business had revenue of $52.06 million for the quarter, compared to the consensus estimate of $27.00 million. Beigene had a negative return on equity of 68.64% and a negative net margin of 284.45%. Research analysts predict that Beigene Ltd will post -19.86 earnings per share for the current fiscal year.

Several brokerages recently issued reports on BGNE. ValuEngine lowered Beigene from a “buy” rating to a “hold” rating in a research note on Thursday, July 2nd. Maxim Group restated a “buy” rating and set a $250.00 price target (up from $190.00) on shares of Beigene in a research note on Friday, July 10th. Zacks Investment Research upgraded Beigene from a “hold” rating to a “buy” rating and set a $251.00 price target on the stock in a research note on Tuesday. SVB Leerink boosted their price target on Beigene from $207.00 to $210.00 and gave the company an “outperform” rating in a research note on Wednesday, June 3rd. Finally, Morgan Stanley lifted their price objective on Beigene from $190.00 to $235.00 and gave the company an “overweight” rating in a report on Wednesday, July 15th. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $218.13.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Capital International Investors boosted its holdings in shares of Beigene by 25.4% in the 1st quarter. Capital International Investors now owns 5,706,609 shares of the company’s stock worth $702,544,000 after acquiring an additional 1,155,679 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Beigene by 1.7% in the 1st quarter. BlackRock Inc. now owns 1,992,628 shares of the company’s stock worth $245,313,000 after acquiring an additional 32,639 shares in the last quarter. Primecap Management Co. CA boosted its holdings in shares of Beigene by 70.2% in the 1st quarter. Primecap Management Co. CA now owns 1,700,021 shares of the company’s stock worth $209,290,000 after acquiring an additional 701,444 shares in the last quarter. State Street Corp boosted its holdings in shares of Beigene by 11.0% in the 1st quarter. State Street Corp now owns 848,980 shares of the company’s stock worth $104,518,000 after acquiring an additional 84,190 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of Beigene by 5.7% in the 1st quarter. Invesco Ltd. now owns 661,070 shares of the company’s stock worth $81,385,000 after acquiring an additional 35,523 shares in the last quarter. 63.78% of the stock is currently owned by institutional investors and hedge funds.

Beigene Company Profile

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.

Featured Article: What does relative strength index mean?

Insider Buying and Selling by Quarter for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.